A Phase 3 interventional study of Baricitinib and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 409 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 2 that started in 2013, is one of 8 in phase 3, and was the 9th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,877 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one has the largest enrollment, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 24th registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.
The study provides 7 years of additional treatment with baricitinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
Drug: Baricitinib · Drug: Placebo
2 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
Drug: Baricitinib · Drug: Placebo
2 mg Baricitinib administered orally once daily in the 96-week Step-down period. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
Drug: Baricitinib
4 mg Baricitinib administered orally once daily in the 96-week Step-down period. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
Drug: Baricitinib
Administered orally
Also known as: LY 3009104, INCB 028050
Administered orally
Number of Participants Who Experienced Adverse Events (AEs) or Serious AE
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (i.e., abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Non-serious AEs are reported at a threshold of 5%. An SAE is an AE from this study that results in any of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, considered significant by the investigator for any other reason A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.
Time frame: Baseline through 84 Months
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response
Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response
Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response
Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
Time frame: Year 5 after entry into JADY
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
Time frame: Baseline, Year 1
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
Time frame: Baseline, Year 3
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS)
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
Time frame: Baseline, Year 5
Percentage of Participants With mTSS Change ≤0
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
Time frame: Year 1 after entry into JADY
Percentage of Participants With mTSS Change ≤0
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
Time frame: Year 3 after entry into JADY
Percentage of Participants With mTSS Change ≤0
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
Time frame: Year 5 after entry into JADY
Change From Baseline of Originating Study in Joint Space Narrowing at Year 1
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.
Time frame: Baseline, Year 1
Change From Baseline of Originating Study in Joint Space Narrowing at Year 3
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.
Time frame: Baseline, Year 3
Change From Baseline of Originating Study in Joint Space Narrowing at Year 5
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing
Time frame: Baseline, Year 5
Change From Baseline of Originating Study in Duration of Morning Stiffness
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Time frame: Baseline, Year 1
Change From Baseline of Originating Study in Duration of Morning Stiffness
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Time frame: Baseline, Year 3
Change From Baseline of Originating Study in Duration of Morning Stiffness
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Time frame: Baseline, Year 5
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
Time frame: Baseline, Year 1
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
Time frame: Baseline, Year 3
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
Time frame: Baseline, Year 5
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
Time frame: Baseline, Year 1
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
Time frame: Baseline, Year 3
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
Time frame: Baseline, Year 5
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Years 5 after entry into JADY
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.8
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Time frame: Year 5 after entry into JADY
Change From Baseline of Originating Study in Bone Erosion Score
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.
Time frame: Baseline, Year 1
Change From Baseline of Originating Study in Bone Erosion Score
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.
Time frame: Baseline, Year 3
Change From Baseline of Originating Study in Bone Erosion Score
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.
Time frame: Baseline, Year 5
Healthcare Resource Utilization
Number of visits to medical care providers related to treatment of Rheumatoid Arthritis (RA) outside of the clinical study. Reported here are healthcare consultations and emergency room consultations from end of originating study to end of participation in study JADY.
Time frame: Baseline up to 84 Months
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.
Time frame: Year 5 after entry into JADY
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.
Time frame: Year 1 after entry into JADY
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.
Time frame: Year 3 after entry into JADY
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.
Time frame: Year 5 after entry into JADY
Percentage of Participants With Relapse Event During the 96-Week Step-Down Period
Relapse is defined as a Clinical Disease Activity Index score \> 10. The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. Total number of participants at risk multiplied by estimate of cumulative event probability would need to be rounded up or down to get a whole number.
Time frame: Week 0 through Week 96 of Step-down
Participants were eligible to participate in the Step-down period if they achieved a sustained (at least 3 months in JADY) low disease activity (CDAI score ≤10; for participants originating in Studies JADV, JADX, JADW, and JAGS) or sustained remission (CDAI score ≤2.8; for participants originating in Study JADZ). Eligible participants were randomized to 4 mg or 2 mg baricitinib once daily to evaluate if treatment with 2 mg maintains the low disease activity achieved with 4 mg baricitinib.
| Milestone | JADZ 4 Milligram (mg) Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib | 2 mg Baricitinib Step-down | 4 mg Baricitinib Step-down |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 451 | 1091 | 180 | 403 | 117 | 331 | 221 | 83 | 0 | 0 |
| Received at least once dose of study drug | 451 | 1090 | 180 | 403 | 117 | 331 | 221 | 83 | 0 | 0 |
| Completed | 19 | 64 | 49 | 120 | 27 | 81 | 0 | 55 | 0 | 0 |
| Not completed | 432 | 1027 | 131 | 283 | 90 | 250 | 221 | 28 | 0 | 0 |
| Withdrew: Adverse event | 52 | 136 | 30 | 73 | 17 | 72 | 24 | 5 | 0 | 0 |
| Withdrew: Death | 13 | 33 | 5 | 9 | 2 | 10 | 3 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 12 | 33 | 10 | 23 | 24 | 58 | 9 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 19 | 7 | 9 | 2 | 8 | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 19 | 21 | 5 | 12 | 9 | 24 | 4 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 5 | 0 | 3 | 1 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 245 | 648 | 49 | 90 | 20 | 38 | 162 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 72 | 132 | 25 | 63 | 15 | 34 | 17 | 10 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | JADZ 4 Milligram (mg) Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib | 2 mg Baricitinib Step-down | 4 mg Baricitinib Step-down |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 592 | 594 |
| Complete through week 96 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 407 | 455 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 523 | 533 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 61 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 38 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 15 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (i.e., abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Non-serious AEs are reported at a threshold of 5%. An SAE is an AE from this study that results in any of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, considered significant by the investigator for any other reason A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.
| participants | 2 mg Baricitinib | 4 mg Baricitinib | 2 mg Baricitinib Step-down | 4 mg Baricitinib Step-down |
|---|---|---|---|---|
| Adverse Events | 234 | 1532 | 270 | 315 |
| Serious Adverse Events | 112 | 517 | 164 | 178 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
| Percentage of Participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20 | 92.6 (89.7 to 94.7) | 88.4 (86.3 to 90.2) | 79.3 (72.6 to 84.7) | 79.5 (75.1 to 83.3) | 72.3 (62.9 to 80.1) | 70.8 (65.2 to 75.9) | 86.7 (81.4 to 90.6) | 75.6 (65.1 to 83.8) |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20 | 78.3 (74.1 to 82.0) | 76.6 (73.9 to 79.1) | 71.6 (64.4 to 77.9) | 70.5 (65.6 to 74.9) | 57.4 (47.7 to 66.6) | 55.8 (49.9 to 61.6) | 73.8 (67.5 to 79.3) | 71.8 (61.0 to 80.6) |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20 | 67.3 (62.7 to 71.6) | 65.6 (62.6 to 68.4) | 60.4 (52.8 to 67.4) | 56.0 (50.9 to 61.0) | 50.5 (40.9 to 60.0) | 43.1 (37.3 to 49.0) | 24.8 (19.4 to 31.0) | 60.3 (49.2 to 70.4) |
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50 | 80.0 (75.9 to 83.5) | 67.7 (64.8 to 70.5) | 58.0 (50.5 to 65.2) | 58.2 (53.1 to 63.1) | 45.5 (36.2 to 55.2) | 43.8 (38.0 to 49.7) | 69.0 (62.5 to 74.9) | 43.6 (33.1 to 54.6) |
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50 | 67.8 (63.2 to 72.1) | 61.6 (58.6 to 64.5) | 49.7 (42.3 to 57.2) | 53.3 (48.2 to 58.3) | 43.6 (34.3 to 53.3) | 36.5 (31.0 to 42.3) | 59.0 (52.3 to 65.5) | 43.6 (33.1 to 54.6) |
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50 | 59.9 (55.1 to 64.5) | 52.7 (49.7 to 55.7) | 44.4 (37.1 to 51.9) | 43.2 (38.2 to 48.3) | 37.6 (28.8 to 47.4) | 32.1 (26.9 to 37.9) | 18.6 (13.9 to 24.4) | 37.2 (27.3 to 48.3) |
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70 | 61.3 (56.6 to 65.9) | 45.7 (42.7 to 48.8) | 34.9 (28.1 to 42.4) | 35.8 (31.1 to 40.8) | 28.7 (20.8 to 38.2) | 25.9 (21.1 to 31.4) | 42.9 (36.4 to 49.6) | 26.9 (18.3 to 37.7) |
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70 | 54.4 (49.6 to 59.1) | 44.1 (41.1 to 47.1) | 35.5 (28.7 to 43.0) | 32.5 (27.9 to 37.5) | 24.8 (17.4 to 34.0) | 21.5 (17.1 to 26.8) | 35.2 (29.1 to 41.9) | 21.8 (14.1 to 32.2) |
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
| percentage of participants | JADZ 4 Milligram (mg) Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70 | 48.2 (43.5 to 53.0) | 39.1 (36.1 to 42.1) | 28.4 (22.1 to 35.6) | 28.4 (24.0 to 33.2) | 23.8 (16.5 to 32.9) | 18.2 (14.1 to 23.2) | 12.9 (9.0 to 18.1) | 19.2 (12.0 to 29.3) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2 | 81.9 (77.9 to 85.3) | 71.9 (69.0 to 74.5) | 66.3 (58.9 to 73.0) | 68.6 (63.7 to 73.1) | 50.5 (40.9 to 60.0) | 51.1 (45.2 to 57.0) | 72.4 (66.0 to 78.0) | 59.0 (47.9 to 69.2) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2 | 71.8 (67.3 to 75.9) | 65.5 (62.5 to 68.3) | 59.2 (51.6 to 66.3) | 59.3 (54.2 to 64.2) | 47.5 (38.1 to 57.2) | 41.6 (35.9 to 47.5) | 61.0 (54.2 to 67.3) | 60.3 (49.2 to 70.4) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2 | 61.1 (56.3 to 65.6) | 58.9 (55.9 to 61.9) | 46.7 (39.4 to 54.3) | 50.0 (44.9 to 55.1) | 44.6 (35.2 to 54.3) | 34.3 (28.9 to 40.1) | 21.0 (16.0 to 27.0) | 53.8 (42.9 to 64.5) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| percentage of participants | JADZ 4 Milligram (mg) Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6 | 65.6 (61.0 to 70.0) | 52.3 (49.3 to 55.4) | 50.9 (43.4 to 58.3) | 46.2 (41.1 to 51.3) | 34.7 (26.1 to 44.3) | 32.8 (27.6 to 38.6) | 52.4 (45.6 to 59.0) | 44.9 (34.3 to 55.9) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6 | 59.9 (55.1 to 64.5) | 51.0 (47.9 to 54.0) | 43.8 (36.5 to 51.3) | 43.2 (38.2 to 48.3) | 31.7 (23.4 to 41.3) | 26.3 (21.4 to 31.8) | 38.6 (32.2 to 45.3) | 35.9 (26.1 to 47.0) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6 | 51.1 (46.3 to 55.8) | 44.0 (41.0 to 47.0) | 36.1 (29.2 to 43.6) | 37.7 (32.9 to 42.8) | 29.7 (21.7 to 39.2) | 26.6 (21.8 to 32.2) | 13.3 (9.4 to 18.6) | 43.6 (33.1 to 54.6) |
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2 | 61.8 (57.1 to 66.3) | 48.4 (45.3 to 51.4) | 46.2 (38.8 to 53.7) | 48.4 (43.3 to 53.5) | 31.7 (23.4 to 41.3) | 31.8 (26.5 to 37.5) | 41.0 (34.5 to 47.7) | 35.9 (26.1 to 47.0) |
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2 | 54.4 (49.6 to 59.1) | 46.1 (43.1 to 49.2) | 40.2 (33.1 to 47.8) | 41.0 (36.1 to 46.1) | 22.8 (15.7 to 31.9) | 23.7 (19.1 to 29.1) | 33.8 (27.8 to 40.4) | 37.2 (27.3 to 48.3) |
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2 | 48.7 (43.9 to 53.5) | 41.3 (38.3 to 44.3) | 36.1 (29.2 to 43.6) | 32.5 (27.9 to 37.5) | 23.8 (16.5 to 32.9) | 21.9 (17.4 to 27.2) | 11.4 (7.8 to 16.4) | 37.2 (27.3 to 48.3) |
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6 | 36.8 (32.3 to 41.5) | 29.3 (26.6 to 32.2) | 24.3 (18.4 to 31.2) | 26.8 (22.5 to 31.5) | 20.8 (14.0 to 29.7) | 13.1 (9.6 to 17.7) | 25.2 (19.8 to 31.5) | 15.4 (9.0 to 25.0) |
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6 | 38.9 (34.4 to 43.7) | 24.7 (22.1 to 27.4) | 24.3 (18.4 to 31.2) | 23.2 (19.2 to 27.8) | 15.8 (10.0 to 24.2) | 10.2 (7.2 to 14.4) | 19.5 (14.7 to 25.4) | 23.1 (15.1 to 33.6) |
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6 | 31.3 (27.0 to 35.9) | 23.9 (21.4 to 26.6) | 22.5 (16.8 to 29.4) | 19.4 (15.7 to 23.8) | 11.9 (6.9 to 19.6) | 8.8 (6.0 to 12.7) | 7.1 (4.4 to 11.4) | 19.2 (12.0 to 29.3) |
Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response | 30.5 (26.3 to 35.1) | 20.8 (18.4 to 23.4) | 17.8 (12.7 to 24.2) | 17.8 (14.2 to 22.0) | 8.9 (4.8 to 16.1) | 9.5 (6.6 to 13.5) | 17.1 (12.6 to 22.8) | 12.8 (7.1 to 22.0) |
Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response | 30.8 (26.6 to 35.4) | 20.3 (18.0 to 22.9) | 16.6 (11.7 to 22.9) | 15.0 (11.7 to 19.1) | 9.9 (5.5 to 17.3) | 8.0 (5.4 to 11.9) | 11.9 (8.2 to 17.0) | 15.4 (9.0 to 25.0) |
Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response | 26.5 (22.5 to 30.9) | 17.7 (15.5 to 20.1) | 13.6 (9.2 to 19.6) | 14.2 (11.0 to 18.2) | 6.9 (3.4 to 13.6) | 7.3 (4.8 to 11.0) | 5.2 (2.9 to 9.1) | 15.4 (9.0 to 25.0) |
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
No measurements were reported for this outcome.
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS) | 1.30 (0.94 to 1.67) | 1.64 (1.38 to 1.90) | 1.13 (0.61 to 1.66) | 1.13 (0.78 to 1.48) | — | — | 1.20 (0.61 to 1.80) | — |
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS) | 1.64 (1.18 to 2.09) | 2.18 (1.85 to 2.51) | 1.32 (0.69 to 1.96) | 1.58 (1.15 to 2.02) | — | — | — | — |
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
No measurements were reported for this outcome.
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With mTSS Change ≤0 | 53.5 (48.7 to 58.2) | 53.0 (50.0 to 56.0) | 0.6 (0.1 to 3.3) | 0.8 (0.3 to 2.4) | — | — | 0 (0.0 to 1.8) | — |
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With mTSS Change ≤0 | 1.7 (0.8 to 3.4) | 0.6 (0.3 to 1.3) | 0 (0.0 to 2.2) | 0.5 (0.1 to 2.0) | — | — | 0 (0.0 to 1.8) | — |
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.
No measurements were reported for this outcome.
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Joint Space Narrowing at Year 3 | 0.45 (0.26 to 0.63) | 0.72 (0.59 to 0.86) | 0.54 (0.25 to 0.83) | 0.44 (0.24 to 0.63) | — | — | 0.52 (0.23 to 0.82) | — |
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Joint Space Narrowing at Year 5 | 0.59 (0.36 to 0.83) | 1.00 (0.84 to 1.17) | 0.68 (0.34 to 1.02) | 0.60 (0.37 to 0.83) | — | — | — | — |
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
| minutes | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Duration of Morning Stiffness | -102.72 ± 155.27 | -73.53 ± 144.22 | — | — | -75.07 ± 139.00 | -73.88 ± 149.55 | -68.74 ± 148.34 | -37.12 ± 61.34 |
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
| minutes | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Duration of Morning Stiffness | -112.41 ± 159.78 | -77.78 ± 141.01 | — | — | -84.60 ± 127.85 | -67.79 ± 154.05 | -90.61 ± 147.70 | -47.13 ± 52.97 |
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
| minutes | JADZ 4 Milligram (mg) Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Duration of Morning Stiffness | -111.45 ± 164.74 | -82.48 ± 137.23 | — | — | -88.37 ± 146.73 | -91.57 ± 163.88 | -92.75 ± 125.39 | -45.89 ± 60.43 |
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
| score on a scale | JADZ 4 Milligram (mg) Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| UK | 0.28 ± 0.26 | 0.23 ± 0.24 | 0.19 ± 0.26 | 0.20 ± 0.23 | 0.21 ± 0.22 | 0.19 ± 0.24 | 0.20 ± 0.26 | — |
| US | 0.19 ± 0.18 | 0.16 ± 0.17 | 0.13 ± 0.18 | 0.14 ± 0.16 | 0.14 ± 0.15 | 0.13 ± 0.16 | 0.14 ± 0.18 | — |
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| UK | 0.33 ± 0.24 | 0.24 ± 0.25 | 0.20 ± 0.26 | 0.21 ± 0.26 | 0.21 ± 0.22 | 0.22 ± 0.25 | 0.24 ± 0.24 | — |
| US | 0.23 ± 0.17 | 0.17 ± 0.17 | 0.15 ± 0.18 | 0.15 ± 0.18 | 0.14 ± 0.15 | 0.15 ± 0.17 | 0.17 ± 0.17 | — |
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| UK | 0.35 ± 0.24 | 0.26 ± 0.26 | 0.19 ± 0.25 | 0.20 ± 0.26 | 0.21 ± 0.22 | 0.22 ± 0.30 | 0.25 ± 0.26 | — |
| US | 0.24 ± 0.16 | 0.18 ± 0.18 | 0.13 ± 0.17 | 0.14 ± 0.18 | 0.15 ± 0.15 | 0.15 ± 0.20 | 0.18 ± 0.18 | — |
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
| millimeter (mm) | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health) | 24.69 ± 28.50 | 19.72 ± 28.17 | 15.13 ± 26.78 | 18.32 ± 26.35 | 20.96 ± 24.53 | 14.98 ± 30.21 | 18.47 ± 27.31 | — |
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
| mm | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health) | 28.48 ± 29.88 | 22.10 ± 28.02 | 16.29 ± 25.37 | 16.48 ± 30.24 | 23.53 ± 24.70 | 18.79 ± 30.03 | 21.45 ± 29.64 | — |
The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
| mm | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health) | 31.13 ± 28.15 | 23.93 ± 28.45 | 13.82 ± 29.59 | 19.34 ± 27.48 | 26.19 ± 27.09 | 23.57 ± 31.67 | 27.31 ± 27.19 | — |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10 | 81.6 (77.6 to 85.0) | 75.3 (72.6 to 77.9) | 68.6 (61.3 to 75.2) | 69.9 (65.1 to 74.4) | 52.5 (42.8 to 61.9) | 50.7 (44.8 to 56.6) | 73.3 (67.0 to 78.9) | 60.3 (49.2 to 70.4) |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10 | 73.3 (68.8 to 77.3) | 67.7 (64.8 to 70.5) | 60.4 (52.8 to 67.4) | 60.4 (55.3 to 65.3) | 49.5 (40.0 to 59.1) | 44.5 (38.8 to 50.4) | 61.4 (54.7 to 67.8) | 56.4 (45.4 to 66.9) |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10 | 61.6 (56.8 to 66.1) | 61.1 (58.1 to 64.0) | 51.5 (44.0 to 58.9) | 54.6 (49.5 to 59.7) | 44.6 (35.2 to 54.3) | 35.4 (30.0 to 41.2) | 21.9 (16.8 to 28.0) | 56.4 (45.4 to 66.9) |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.8 | 44.9 (40.2 to 49.7) | 28.3 (25.7 to 31.2) | 21.9 (16.3 to 28.7) | 25.1 (21.0 to 29.8) | 16.8 (10.8 to 25.3) | 13.5 (10.0 to 18.1) | 22.9 (17.7 to 29.0) | 14.1 (8.1 to 23.5) |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8 | 40.1 (35.5 to 44.9) | 30.0 (27.3 to 32.8) | 21.9 (16.3 to 28.7) | 23.5 (19.4 to 28.1) | 22.8 (15.7 to 31.9) | 15.0 (11.2 to 19.7) | 18.6 (13.9 to 24.4) | 20.5 (13.0 to 30.8) |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8 | 33.9 (29.5 to 38.6) | 25.0 (22.5 to 27.8) | 19.5 (14.3 to 26.2) | 22.4 (18.4 to 27.0) | 15.8 (10.0 to 24.2) | 12.8 (9.3 to 17.2) | 8.1 (5.1 to 12.6) | 19.2 (12.0 to 29.3) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22 | 89.7 (86.5 to 92.3) | 81.4 (78.9 to 83.7) | 78.7 (71.9 to 84.2) | 75.4 (70.7 to 79.5) | 74.3 (65.0 to 81.8) | 69.3 (63.6 to 74.5) | 80.0 (74.1 to 84.8) | 48.7 (37.9 to 59.6) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22 | 75.4 (71.1 to 79.3) | 70.4 (67.6 to 73.1) | 64.5 (57.0 to 71.3) | 63.4 (58.3 to 68.2) | 56.4 (46.7 to 65.7) | 54.4 (48.5 to 60.2) | 68.1 (61.5 to 74.0) | 47.4 (36.7 to 58.4) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22 | 65.2 (60.5 to 69.6) | 58.5 (55.5 to 61.5) | 51.5 (44.0 to 58.9) | 51.4 (46.3 to 56.4) | 50.5 (40.9 to 60.0) | 39.4 (33.8 to 45.3) | 20.0 (15.2 to 25.9) | 39.7 (29.6 to 50.8) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3 | 85.4 (81.7 to 88.5) | 75.6 (72.9 to 78.1) | 72.8 (65.6 to 78.9) | 69.4 (64.5 to 73.9) | 65.3 (55.7 to 73.9) | 61.7 (55.8 to 67.2) | 75.2 (69.0 to 80.6) | 43.6 (33.1 to 54.6) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3 | 72.6 (68.1 to 76.6) | 64.8 (61.8 to 67.6) | 61.5 (54.0 to 68.5) | 58.5 (53.4 to 63.4) | 50.5 (40.9 to 60.0) | 47.8 (42.0 to 53.7) | 63.8 (57.1 to 70.0) | 38.5 (28.4 to 49.6) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3 | 62.8 (58.0 to 67.3) | 53.4 (50.3 to 56.4) | 46.7 (39.4 to 54.3) | 46.2 (41.1 to 51.3) | 46.5 (37.1 to 56.2) | 35.0 (29.6 to 40.9) | 19.5 (14.7 to 25.4) | 34.6 (25.0 to 45.7) |
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.
No measurements were reported for this outcome.
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Bone Erosion Score | 0.85 (0.63 to 1.08) | 0.92 (0.76 to 1.07) | 0.59 (0.30 to 0.89) | 0.69 (0.49 to 0.89) | — | — | 0.68 (0.32 to 1.03) | — |
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion. LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.
| score on a scale | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of Originating Study in Bone Erosion Score | 1.04 (0.77 to 1.32) | 1.18 (0.98 to 1.38) | 0.65 (0.28 to 1.01) | 0.98 (0.74 to 1.23) | — | — | — | — |
Number of visits to medical care providers related to treatment of Rheumatoid Arthritis (RA) outside of the clinical study. Reported here are healthcare consultations and emergency room consultations from end of originating study to end of participation in study JADY.
| consultations | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Healthcare Consultations | 3134 | 11108 | 2160 | 4573 | 2380 | 5410 | 717 | 749 |
| Emergency Room Consultations | 95 | 244 | 52 | 131 | 73 | 154 | 40 | 16 |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11 | 81.6 (77.6 to 85.0) | 75.2 (72.5 to 77.8) | 70.4 (63.1 to 76.8) | 69.1 (64.2 to 73.6) | 53.5 (43.8 to 62.9) | 53.6 (47.7 to 59.5) | 72.4 (66.0 to 78.0) | 59.0 (47.9 to 69.2) |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11 | 73.3 (68.8 to 77.3) | 67.8 (64.9 to 70.6) | 60.9 (53.4 to 68.0) | 62.3 (57.2 to 67.1) | 48.5 (39.0 to 58.1) | 44.5 (38.8 to 50.4) | 60.0 (53.3 to 66.4) | 57.7 (46.6 to 68.0) |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11 | 61.3 (56.6 to 65.9) | 61.2 (58.2 to 64.1) | 51.5 (44.0 to 58.9) | 53.3 (48.2 to 58.3) | 46.5 (37.1 to 56.2) | 35.4 (30.0 to 41.2) | 23.3 (18.1 to 29.5) | 57.7 (46.6 to 68.0) |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3 | 45.3 (40.6 to 50.1) | 28.9 (26.2 to 31.8) | 24.3 (18.4 to 31.2) | 23.5 (19.4 to 28.1) | 13.9 (8.4 to 21.9) | 13.1 (9.6 to 17.7) | 22.9 (17.7 to 29.0) | 14.1 (8.1 to 23.5) |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3 | 39.9 (35.3 to 44.6) | 29.8 (27.1 to 32.6) | 22.5 (16.8 to 29.4) | 21.6 (17.7 to 26.1) | 19.8 (13.2 to 28.6) | 13.5 (10.0 to 18.1) | 15.7 (11.4 to 21.2) | 21.8 (14.1 to 32.2) |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.
| percentage of participants | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3 | 34.8 (30.4 to 39.5) | 24.7 (22.1 to 27.4) | 20.7 (15.3 to 27.4) | 21.3 (17.4 to 25.8) | 13.9 (8.4 to 21.9) | 11.3 (8.1 to 15.6) | 8.1 (5.1 to 12.6) | 21.8 (14.1 to 32.2) |
Relapse is defined as a Clinical Disease Activity Index score \> 10. The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. Total number of participants at risk multiplied by estimate of cumulative event probability would need to be rounded up or down to get a whole number.
| percentage of participants | 2 mg Baricitinib Step-down | 4 mg Baricitinib Step-down |
|---|---|---|
| Week 12 | 11.8 | 5.4 |
| Week 24 | 26.0 | 12.5 |
| Week 36 | 31.0 | 18.2 |
| Week 48 | 36.0 | 21.1 |
| Week 60 | 41.0 | 26.6 |
| Week 72 | 45.1 | 29.1 |
| Week 84 | 46.7 | 31.0 |
| Week 96 | 47.8 | 34.5 |
Collected over Baseline up to 84 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 mg Baricitinib | 7/297 (2.4%) | 112/297 (37.7%) | 234/297 (78.8%) |
| 4 mg Baricitinib | 70/2,579 (2.7%) | 517/2,579 (20%) | 1,532/2,579 (59.4%) |
| 2 mg Baricitinib Step-Down | 4/592 (0.7%) | 164/592 (27.7%) | 270/592 (45.6%) |
| 4 mg Baricitinib Step-Down | 4/594 (0.7%) | 178/594 (30%) | 315/594 (53%) |
| Event | 2 mg Baricitinib | 4 mg Baricitinib | 2 mg Baricitinib Step-Down | 4 mg Baricitinib Step-Down |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 15/297 | 34/2579 | 10/592 | 12/594 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 8/297 | 42/2579 | 6/592 | 5/594 |
| CholelithiasisHepatobiliary disorders | 0/297 | 8/2579 | 1/592 | 10/594 |
| Herpes zosterInfections and infestations | 5/297 | 15/2579 | 2/592 | 5/594 |
| Ischaemic strokeNervous system disorders | 5/297 | 1/2579 | 0/592 | 0/594 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/297 | 18/2579 | 5/592 | 3/594 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/66 | 3/548 | 2/152 | 0/146 |
| Acute myocardial infarctionCardiac disorders | 4/297 | 7/2579 | 1/592 | 1/594 |
| Atrial fibrillationCardiac disorders | 4/297 | 11/2579 | 1/592 | 3/594 |
| Urinary tract infectionInfections and infestations | 4/297 | 12/2579 | 0/592 | 3/594 |
| Event | 2 mg Baricitinib | 4 mg Baricitinib | 2 mg Baricitinib Step-Down | 4 mg Baricitinib Step-Down |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 58/297 | 281/2579 | 46/592 | 51/594 |
| Urinary tract infectionInfections and infestations | 53/297 | 241/2579 | 34/592 | 52/594 |
| BronchitisInfections and infestations | 48/297 | 291/2579 | 44/592 | 65/594 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 43/297 | 155/2579 | 0/592 | 0/594 |
| NasopharyngitisInfections and infestations | 42/297 | 291/2579 | 54/592 | 58/594 |
| Back painMusculoskeletal and connective tissue disorders | 42/297 | 162/2579 | 35/592 | 36/594 |
| HypertensionVascular disorders | 33/297 | 196/2579 | 38/592 | 46/594 |
| Herpes zosterInfections and infestations | 30/297 | 160/2579 | 39/592 | 53/594 |
| InfluenzaInfections and infestations | 15/297 | 147/2579 | 30/592 | 56/594 |
| CoughRespiratory, thoracic and mediastinal disorders | 28/297 | 105/2579 | 35/592 | 25/594 |
All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 386 | 881 | 150 | 335 | 86 | 253 | 199 | 68 | 2358 |
| >=65 years | 65 | 209 | 30 | 68 | 31 | 78 | 22 | 15 | 518 |
| Sex: Female, Male(Participants) | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 326 | 847 | 144 | 335 | 87 | 275 | 177 | 71 | 2262 |
| Male | 125 | 243 | 36 | 68 | 30 | 56 | 44 | 12 | 614 |
| Race (NIH/OMB)(Participants) | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 35 | 56 | 1 | 12 | 6 | 21 | 6 | 6 | 143 |
| Asian | 122 | 321 | 50 | 94 | 6 | 19 | 167 | 2 | 781 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 17 | 4 | 9 | 10 | 7 | 12 | 3 | 2 | 64 |
| White | 275 | 691 | 119 | 283 | 98 | 275 | 45 | 73 | 1859 |
| More than one race | 2 | 17 | 1 | 2 | 0 | 1 | 0 | 0 | 23 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 3 | 0 | 0 | 5 |
| Region of Enrollment(Participants) | JADZ 4 mg Baricitinib | JADV 4 mg Baricitinib | JADX 2 mg Baricitinib | JADX 4 mg Baricitinib | JADW 2 mg Baricitinib | JADW 4 mg Baricitinib | JAGS 4 mg Baricitinib | JADA 4 mg Baricitinib | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 68 | 64 | 39 | 103 | 52 | 136 | 0 | 26 | 488 |
| Czechia | 0 | 29 | 3 | 10 | 0 | 0 | 0 | 14 | 56 |
| Portugal | 3 | 3 | 2 | 3 | 0 | 0 | 0 | 0 | 11 |
| Russia | 35 | 70 | 10 | 7 | 0 | 0 | 0 | 0 | 122 |
| Greece | 0 | 2 | 0 | 0 | 2 | 4 | 0 | 0 | 8 |
| South Korea | 6 | 43 | 6 | 8 | 3 | 6 | 0 | 0 | 72 |
| Latvia | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Sweden | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Austria | 2 | 0 | 0 | 0 | 3 | 12 | 0 | 0 | 17 |
| Netherlands | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| China | 0 | 41 | 0 | 0 | 0 | 0 | 167 | 0 | 208 |
| Poland | 0 | 66 | 11 | 37 | 9 | 22 | 0 | 11 | 156 |
| Brazil | 16 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 30 |
| Slovenia | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Slovakia | 0 | 17 | 3 | 7 | 0 | 0 | 0 | 0 | 27 |
| France | 0 | 16 | 0 | 0 | 6 | 14 | 0 | 0 | 36 |
| Lithuania | 0 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 21 |
| Croatia | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 6 | 9 |
| Argentina | 87 | 226 | 15 | 44 | 3 | 15 | 40 | 0 | 430 |
| Romania | 0 | 14 | 2 | 2 | 0 | 0 | 0 | 3 | 21 |
| Hungary | 0 | 30 | 8 | 11 | 0 | 0 | 0 | 11 | 60 |
| Japan | 82 | 215 | 4 | 13 | 3 | 11 | 0 | 0 | 328 |
| United Kingdom | 10 | 8 | 3 | 1 | 1 | 3 | 0 | 0 | 26 |
| Switzerland | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 7 |
| India | 28 | 0 | 16 | 27 | 0 | 0 | 0 | 0 | 71 |
| Spain | 0 | 28 | 9 | 24 | 6 | 19 | 0 | 0 | 86 |
| Canada | 13 | 8 | 8 | 13 | 3 | 2 | 0 | 0 | 47 |
| Turkey | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 3 |
| Belgium | 20 | 7 | 3 | 8 | 0 | 3 | 0 | 0 | 41 |
| Taiwan | 0 | 12 | 23 | 46 | 0 | 0 | 0 | 0 | 81 |
| Denmark | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 5 |
| South Africa | 16 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 56 |
| Italy | 12 | 0 | 3 | 6 | 3 | 3 | 0 | 0 | 27 |
| Mexico | 39 | 115 | 8 | 14 | 5 | 21 | 0 | 12 | 214 |
| Israel | 0 | 0 | 0 | 0 | 6 | 21 | 0 | 0 | 27 |
| Australia | 0 | 0 | 1 | 12 | 5 | 14 | 0 | 0 | 32 |
| Germany | 11 | 2 | 1 | 6 | 3 | 13 | 0 | 0 | 36 |
Showing the first 100 of 409 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2013 to primary completion in Nov 2020, 88 months.
Results were first posted in Feb 2022, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 88 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib